Funding for this research was provided by:
European Community’s Seventh Framework Programme (602270)
Received: 3 May 2017
Accepted: 6 February 2018
First Online: 14 February 2018
Ethics approval and consent to participate
: Brunel University Research Ethics Committee (UK) reviewed this research and gave full ethical clearance. Respective authorities in sample countries (Ethik-Kommission, Bayerische Landesärztekammer fromGermany, Egészségügyi Tudományos Tanács, Tudományosés Kutatásetikai Bizottság from Hungary, Parc de SalutMAR - Clinical Research Ethics Committee from Spain and Medisch-ethische toetsingscommissie (METC) azM/UMfrom the Netherlands) also provided clearance. Prospective participants were approached via an introductory email requesting their participation in the study. They were given the information about the project and the confidentiality of their involvement. Respondents were recruited once they consented to participate. Written consent forms were obtained from all respondents included in the study.
: Not applicable.
: All authors, except SP and RW, declare that they have no competing interests. SP is an Associate Editor of this journal. RW undertakes consultancy and research for and receives travel funds and hospitality from manufacturers of smoking cessation medications but does not, and will not take funds from e-cigarette manufacturers or the tobacco industry. RW is an honorary co-director of the National Centre for Smoking Cessation and Training and a Trustee of the stop-smoking charity, QUIT. RW’s salary is funded by Cancer Research UK.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.